A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-06

AUTHORS

Marc C. Chamberlain, Sean Grimm, Surasak Phuphanich, Larry Recht, Jay Z. Zhu, Lyndon Kim, Steve Rosenfeld, Camilo E. Fadul, Brain Tumor Investigational Consortium (BTIC)

ABSTRACT

Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m(2) as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14% and the PFS-1 for Group 2 was 20%. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10% in Group 1; n = 1; 4.2% in Group 2) and stable disease (n = 7; 23% in Group 1; n = 5; 21% in Group 2). In Group 1, 38.7% of patients experienced a serious adverse event; however only 3.2% were potentially attributable to study drug. In Group 2, 44% of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM. More... »

PAGES

335-343

References to SciGraph publications

  • 2012-11. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme in JOURNAL OF NEURO-ONCOLOGY
  • 2005-06. Disrupting tumour blood vessels in NATURE REVIEWS CANCER
  • 2010-01. Salvage therapy with single agent bevacizumab for recurrent glioblastoma in JOURNAL OF NEURO-ONCOLOGY
  • 2006-07. Mechanisms of angiogenesis in gliomas in JOURNAL OF NEURO-ONCOLOGY
  • 2006-08. Drug penetration in solid tumours in NATURE REVIEWS CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y

    DOI

    http://dx.doi.org/10.1007/s11060-014-1437-y

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1031583661

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24740196


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Angiogenesis Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bevacizumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Brain Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease-Free Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glioblastoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quinazolines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Young Adult", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, 825 Eastlake Ave E, MS: G4-940, 98109, Seattle, WA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chamberlain", 
            "givenName": "Marc C.", 
            "id": "sg:person.01326261166.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Northwestern University", 
              "id": "https://www.grid.ac/institutes/grid.16753.36", 
              "name": [
                "Department of Neurology, Northwestern University, 710\u00a0N Lake Shore Drive, Abbott Hall, Room 1110, 60611, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grimm", 
            "givenName": "Sean", 
            "id": "sg:person.0576221411.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576221411.84"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cedars-Sinai Medical Center", 
              "id": "https://www.grid.ac/institutes/grid.50956.3f", 
              "name": [
                "Cedars Sinai Medical Center, 8631\u00a0W 3rd St, Ste 410-E, 90048, Los Angeles, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Phuphanich", 
            "givenName": "Surasak", 
            "id": "sg:person.01346246457.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346246457.67"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Lucile Packard Children's Hospital", 
              "id": "https://www.grid.ac/institutes/grid.414123.1", 
              "name": [
                "Stanford University, 875 Blake Wilbur Dr Rm 2221, 943042205, Palo Alto, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Recht", 
            "givenName": "Larry", 
            "id": "sg:person.01275010460.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275010460.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Tufts University", 
              "id": "https://www.grid.ac/institutes/grid.429997.8", 
              "name": [
                "Tufts University, 750 Washington St, # 833, 02111, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhu", 
            "givenName": "Jay Z.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Jefferson University, 900 Walnut Street, Suite 200, 19107, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kim", 
            "givenName": "Lyndon", 
            "id": "sg:person.0635633346.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635633346.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cleveland Clinic", 
              "id": "https://www.grid.ac/institutes/grid.239578.2", 
              "name": [
                "Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, 9500 Euclid Avenue, Mailcode: NB40, 44195, Cleveland, OH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rosenfeld", 
            "givenName": "Steve", 
            "id": "sg:person.010674622762.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010674622762.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dartmouth\u2013Hitchcock Medical Center", 
              "id": "https://www.grid.ac/institutes/grid.413480.a", 
              "name": [
                "Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, 03756, Lebanon, NH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fadul", 
            "givenName": "Camilo E.", 
            "id": "sg:person.01356122202.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356122202.32"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Brain Tumor Investigational Consortium (BTIC)", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s11060-005-9097-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001104504", 
              "https://doi.org/10.1007/s11060-005-9097-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-005-9097-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001104504", 
              "https://doi.org/10.1007/s11060-005-9097-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/neuonc/not151", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003959313"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2011.39.3934", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009031942"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/0008-5472.can-07-0127", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010238020"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2008.16.3055", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010751135"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1215/15228517-2009-006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011570339"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-09-3106", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014254065"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmc.2006.10.020", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014613992"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1893", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017162057", 
              "https://doi.org/10.1038/nrc1893"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1893", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017162057", 
              "https://doi.org/10.1038/nrc1893"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276673", 
              "https://doi.org/10.1038/nrc1628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276673", 
              "https://doi.org/10.1038/nrc1628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276673", 
              "https://doi.org/10.1038/nrc1628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1586/ern.11.30", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018407035"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2005.04.8801", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021574047"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-012-0964-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030739430", 
              "https://doi.org/10.1007/s11060-012-0964-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2010.01.155", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033299281"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2217/cns.12.5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037403239"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-10-0516", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038106726"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-009-9957-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040541619", 
              "https://doi.org/10.1007/s11060-009-9957-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-009-9957-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040541619", 
              "https://doi.org/10.1007/s11060-009-9957-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2012.41.9242", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042233716"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2008.19.8721", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042965400"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2009.26.3541", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043187529"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmra0708126", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043717119"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1215/15228517-2007-062", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046098276"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2011.36.1311", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047945986"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa043330", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052112015"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm801315b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055956088"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm801315b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055956088"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1212/01.wnl.0000304121.57857.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064350042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1212/01.wnl.0000304121.57857.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064350042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1212/01.wnl.0000304121.57857.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064350042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1215/15228517-2006-025", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064414261"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.1999.17.8.2572", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1074549881"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077005540", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1078716995"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.8531", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083944555"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-06", 
        "datePublishedReg": "2014-06-01", 
        "description": "Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab na\u00efve patients (Group 1). Verubulin was administered at 3.3 mg/m(2) as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14% and the PFS-1 for Group 2 was 20%. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10% in Group 1; n = 1; 4.2% in Group 2) and stable disease (n = 7; 23% in Group 1; n = 5; 21% in Group 2). In Group 1, 38.7% of patients experienced a serious adverse event; however only 3.2% were potentially attributable to study drug. In Group 2, 44% of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab na\u00efve or refractory recurrent GBM.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s11060-014-1437-y", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2438816", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1094205", 
            "issn": [
              "0167-594X", 
              "1573-7373"
            ], 
            "name": "Journal of Neuro-Oncology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "118"
          }
        ], 
        "name": "A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)", 
        "pagination": "335-343", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "96753a3a68bb18df00615a6990c89c3504169041f2af19d1428f7e49b030bea6"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24740196"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "8309335"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11060-014-1437-y"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1031583661"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11060-014-1437-y", 
          "https://app.dimensions.ai/details/publication/pub.1031583661"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T15:05", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000532.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs11060-014-1437-y"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'


     

    This table displays all metadata directly associated to this object as RDF triples.

    311 TRIPLES      21 PREDICATES      78 URIs      39 LITERALS      27 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11060-014-1437-y schema:about N04755408a0ec448f8220846e165cd047
    2 N08db6fb3cc5d4715924dae94637ede0b
    3 N11f4e09225ea46c29132a421dfe7a49d
    4 N2ae9aed0dd3b4b01a018fdf60c3bb659
    5 N2c8c62a80758401d831c63d24e9da4e6
    6 N348465c4652a47afae04ce53dd1537c4
    7 N400bc374432841ca9d86fe13b73d8888
    8 N427e69c858d8455ca348d7b3879281fe
    9 N6520d884143b4b2aafef8b603ba6d954
    10 N73e5775dfabb4f7a8c61164246266626
    11 N747e0c0aa4344bf0b29dedbfc2b61be6
    12 N8761eb3b72b04ad6a3d213407e704608
    13 N999a3c4a18a842ecbfd907f760ad8110
    14 N9efad3abe47c47d2930283cde42e69f0
    15 Nad0d0010d99847b4b009f8e402c05ec8
    16 Nd18a3ae7f39f49d7ba7383622afc812d
    17 Nd6a88eddf7c34574a60c38f78c59f37d
    18 Nf77bb2bb9555401caa8f12962ab25347
    19 anzsrc-for:11
    20 anzsrc-for:1103
    21 schema:author Ndc268ae0c44e4cf3add8c1f4502f9918
    22 schema:citation sg:pub.10.1007/s11060-005-9097-6
    23 sg:pub.10.1007/s11060-009-9957-6
    24 sg:pub.10.1007/s11060-012-0964-7
    25 sg:pub.10.1038/nrc1628
    26 sg:pub.10.1038/nrc1893
    27 https://app.dimensions.ai/details/publication/pub.1077005540
    28 https://doi.org/10.1016/j.bmc.2006.10.020
    29 https://doi.org/10.1016/j.bmcl.2010.01.155
    30 https://doi.org/10.1021/jm801315b
    31 https://doi.org/10.1056/nejmoa043330
    32 https://doi.org/10.1056/nejmra0708126
    33 https://doi.org/10.1093/neuonc/not151
    34 https://doi.org/10.1158/0008-5472.can-07-0127
    35 https://doi.org/10.1158/1078-0432.ccr-09-3106
    36 https://doi.org/10.1158/1535-7163.mct-10-0516
    37 https://doi.org/10.1200/jco.1990.8.7.1277
    38 https://doi.org/10.1200/jco.1999.17.8.2572
    39 https://doi.org/10.1200/jco.2005.04.8801
    40 https://doi.org/10.1200/jco.2008.16.3055
    41 https://doi.org/10.1200/jco.2008.19.8721
    42 https://doi.org/10.1200/jco.2009.26.3541
    43 https://doi.org/10.1200/jco.2010.28.15_suppl.8531
    44 https://doi.org/10.1200/jco.2011.36.1311
    45 https://doi.org/10.1200/jco.2011.39.3934
    46 https://doi.org/10.1200/jco.2012.41.9242
    47 https://doi.org/10.1212/01.wnl.0000304121.57857.38
    48 https://doi.org/10.1215/15228517-2006-025
    49 https://doi.org/10.1215/15228517-2007-062
    50 https://doi.org/10.1215/15228517-2009-006
    51 https://doi.org/10.1586/ern.11.30
    52 https://doi.org/10.2217/cns.12.5
    53 schema:datePublished 2014-06
    54 schema:datePublishedReg 2014-06-01
    55 schema:description Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m(2) as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14% and the PFS-1 for Group 2 was 20%. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10% in Group 1; n = 1; 4.2% in Group 2) and stable disease (n = 7; 23% in Group 1; n = 5; 21% in Group 2). In Group 1, 38.7% of patients experienced a serious adverse event; however only 3.2% were potentially attributable to study drug. In Group 2, 44% of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM.
    56 schema:genre research_article
    57 schema:inLanguage en
    58 schema:isAccessibleForFree false
    59 schema:isPartOf N6e52fa0cfa264f1486c7772f1c6e3e20
    60 Nd6169ab509ee47f0bf70f536c8df2c86
    61 sg:journal.1094205
    62 schema:name A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
    63 schema:pagination 335-343
    64 schema:productId N088fdca56ef74bdc8202d2ab68bd148d
    65 Na0f7a0028a7140f5876f06834844d91e
    66 Nb32ce1c09b494afcac014ca698529f34
    67 Nf5c9607ad3cb464f9affd60abc9e7db6
    68 Nfc45f1965b5645e787c4211d6a3b8ca1
    69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031583661
    70 https://doi.org/10.1007/s11060-014-1437-y
    71 schema:sdDatePublished 2019-04-10T15:05
    72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    73 schema:sdPublisher Nddc807f93b60413c95ec6c3bb31e7a9d
    74 schema:url http://link.springer.com/10.1007%2Fs11060-014-1437-y
    75 sgo:license sg:explorer/license/
    76 sgo:sdDataset articles
    77 rdf:type schema:ScholarlyArticle
    78 N04755408a0ec448f8220846e165cd047 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    79 schema:name Humans
    80 rdf:type schema:DefinedTerm
    81 N065604b8d1cc4176a9a571bee4da0dd6 rdf:first Nb4684fa9008241599e92b949288304c3
    82 rdf:rest rdf:nil
    83 N088fdca56ef74bdc8202d2ab68bd148d schema:name doi
    84 schema:value 10.1007/s11060-014-1437-y
    85 rdf:type schema:PropertyValue
    86 N08db6fb3cc5d4715924dae94637ede0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    87 schema:name Neoplasm Recurrence, Local
    88 rdf:type schema:DefinedTerm
    89 N0a40e50d22a04a35ad5e58842101aebc rdf:first sg:person.0635633346.28
    90 rdf:rest N94fea801578748b995e66457d836da5d
    91 N11f4e09225ea46c29132a421dfe7a49d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Angiogenesis Inhibitors
    93 rdf:type schema:DefinedTerm
    94 N1a325d590a63449ba80ae15bf2012d49 schema:name Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, 825 Eastlake Ave E, MS: G4-940, 98109, Seattle, WA, USA
    95 rdf:type schema:Organization
    96 N2ae9aed0dd3b4b01a018fdf60c3bb659 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Prospective Studies
    98 rdf:type schema:DefinedTerm
    99 N2c8c62a80758401d831c63d24e9da4e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Aged
    101 rdf:type schema:DefinedTerm
    102 N348465c4652a47afae04ce53dd1537c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Middle Aged
    104 rdf:type schema:DefinedTerm
    105 N3d06fa00fb0843d7a83033957d334c8c rdf:first sg:person.0576221411.84
    106 rdf:rest Ne0fa242a80c54b21a93e4b8c6239440c
    107 N400bc374432841ca9d86fe13b73d8888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Adult
    109 rdf:type schema:DefinedTerm
    110 N427e69c858d8455ca348d7b3879281fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Bevacizumab
    112 rdf:type schema:DefinedTerm
    113 N44b75183e9944854a58ad586bff9ae2a rdf:first sg:person.01275010460.24
    114 rdf:rest N5a2dece932834c52a6bae9ab2de70f14
    115 N5a2dece932834c52a6bae9ab2de70f14 rdf:first Nc8f11343a6404bd09080c338b1cb695c
    116 rdf:rest N0a40e50d22a04a35ad5e58842101aebc
    117 N6520d884143b4b2aafef8b603ba6d954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Antineoplastic Agents
    119 rdf:type schema:DefinedTerm
    120 N6e52fa0cfa264f1486c7772f1c6e3e20 schema:volumeNumber 118
    121 rdf:type schema:PublicationVolume
    122 N6f821f54880349819b8fe52238bf5196 schema:name Jefferson University, 900 Walnut Street, Suite 200, 19107, Philadelphia, PA, USA
    123 rdf:type schema:Organization
    124 N73e5775dfabb4f7a8c61164246266626 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Treatment Outcome
    126 rdf:type schema:DefinedTerm
    127 N747e0c0aa4344bf0b29dedbfc2b61be6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Brain Neoplasms
    129 rdf:type schema:DefinedTerm
    130 N8761eb3b72b04ad6a3d213407e704608 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Disease-Free Survival
    132 rdf:type schema:DefinedTerm
    133 N94fea801578748b995e66457d836da5d rdf:first sg:person.010674622762.80
    134 rdf:rest Nf190e53bba5248f89fa259dc0ca91d51
    135 N999a3c4a18a842ecbfd907f760ad8110 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Glioblastoma
    137 rdf:type schema:DefinedTerm
    138 N9efad3abe47c47d2930283cde42e69f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Female
    140 rdf:type schema:DefinedTerm
    141 Na0f7a0028a7140f5876f06834844d91e schema:name pubmed_id
    142 schema:value 24740196
    143 rdf:type schema:PropertyValue
    144 Nad0d0010d99847b4b009f8e402c05ec8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Quinazolines
    146 rdf:type schema:DefinedTerm
    147 Nb32ce1c09b494afcac014ca698529f34 schema:name nlm_unique_id
    148 schema:value 8309335
    149 rdf:type schema:PropertyValue
    150 Nb4684fa9008241599e92b949288304c3 schema:familyName Brain Tumor Investigational Consortium (BTIC)
    151 rdf:type schema:Person
    152 Nc8f11343a6404bd09080c338b1cb695c schema:affiliation https://www.grid.ac/institutes/grid.429997.8
    153 schema:familyName Zhu
    154 schema:givenName Jay Z.
    155 rdf:type schema:Person
    156 Nd18a3ae7f39f49d7ba7383622afc812d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Antibodies, Monoclonal, Humanized
    158 rdf:type schema:DefinedTerm
    159 Nd6169ab509ee47f0bf70f536c8df2c86 schema:issueNumber 2
    160 rdf:type schema:PublicationIssue
    161 Nd6a88eddf7c34574a60c38f78c59f37d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Young Adult
    163 rdf:type schema:DefinedTerm
    164 Ndc268ae0c44e4cf3add8c1f4502f9918 rdf:first sg:person.01326261166.36
    165 rdf:rest N3d06fa00fb0843d7a83033957d334c8c
    166 Nddc807f93b60413c95ec6c3bb31e7a9d schema:name Springer Nature - SN SciGraph project
    167 rdf:type schema:Organization
    168 Ne0fa242a80c54b21a93e4b8c6239440c rdf:first sg:person.01346246457.67
    169 rdf:rest N44b75183e9944854a58ad586bff9ae2a
    170 Nf190e53bba5248f89fa259dc0ca91d51 rdf:first sg:person.01356122202.32
    171 rdf:rest N065604b8d1cc4176a9a571bee4da0dd6
    172 Nf5c9607ad3cb464f9affd60abc9e7db6 schema:name readcube_id
    173 schema:value 96753a3a68bb18df00615a6990c89c3504169041f2af19d1428f7e49b030bea6
    174 rdf:type schema:PropertyValue
    175 Nf77bb2bb9555401caa8f12962ab25347 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Male
    177 rdf:type schema:DefinedTerm
    178 Nfc45f1965b5645e787c4211d6a3b8ca1 schema:name dimensions_id
    179 schema:value pub.1031583661
    180 rdf:type schema:PropertyValue
    181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    182 schema:name Medical and Health Sciences
    183 rdf:type schema:DefinedTerm
    184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    185 schema:name Clinical Sciences
    186 rdf:type schema:DefinedTerm
    187 sg:grant.2438816 http://pending.schema.org/fundedItem sg:pub.10.1007/s11060-014-1437-y
    188 rdf:type schema:MonetaryGrant
    189 sg:journal.1094205 schema:issn 0167-594X
    190 1573-7373
    191 schema:name Journal of Neuro-Oncology
    192 rdf:type schema:Periodical
    193 sg:person.010674622762.80 schema:affiliation https://www.grid.ac/institutes/grid.239578.2
    194 schema:familyName Rosenfeld
    195 schema:givenName Steve
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010674622762.80
    197 rdf:type schema:Person
    198 sg:person.01275010460.24 schema:affiliation https://www.grid.ac/institutes/grid.414123.1
    199 schema:familyName Recht
    200 schema:givenName Larry
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275010460.24
    202 rdf:type schema:Person
    203 sg:person.01326261166.36 schema:affiliation N1a325d590a63449ba80ae15bf2012d49
    204 schema:familyName Chamberlain
    205 schema:givenName Marc C.
    206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
    207 rdf:type schema:Person
    208 sg:person.01346246457.67 schema:affiliation https://www.grid.ac/institutes/grid.50956.3f
    209 schema:familyName Phuphanich
    210 schema:givenName Surasak
    211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346246457.67
    212 rdf:type schema:Person
    213 sg:person.01356122202.32 schema:affiliation https://www.grid.ac/institutes/grid.413480.a
    214 schema:familyName Fadul
    215 schema:givenName Camilo E.
    216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356122202.32
    217 rdf:type schema:Person
    218 sg:person.0576221411.84 schema:affiliation https://www.grid.ac/institutes/grid.16753.36
    219 schema:familyName Grimm
    220 schema:givenName Sean
    221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576221411.84
    222 rdf:type schema:Person
    223 sg:person.0635633346.28 schema:affiliation N6f821f54880349819b8fe52238bf5196
    224 schema:familyName Kim
    225 schema:givenName Lyndon
    226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635633346.28
    227 rdf:type schema:Person
    228 sg:pub.10.1007/s11060-005-9097-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001104504
    229 https://doi.org/10.1007/s11060-005-9097-6
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1007/s11060-009-9957-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040541619
    232 https://doi.org/10.1007/s11060-009-9957-6
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1007/s11060-012-0964-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030739430
    235 https://doi.org/10.1007/s11060-012-0964-7
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1038/nrc1628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017276673
    238 https://doi.org/10.1038/nrc1628
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1038/nrc1893 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017162057
    241 https://doi.org/10.1038/nrc1893
    242 rdf:type schema:CreativeWork
    243 https://app.dimensions.ai/details/publication/pub.1077005540 schema:CreativeWork
    244 https://doi.org/10.1016/j.bmc.2006.10.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014613992
    245 rdf:type schema:CreativeWork
    246 https://doi.org/10.1016/j.bmcl.2010.01.155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033299281
    247 rdf:type schema:CreativeWork
    248 https://doi.org/10.1021/jm801315b schema:sameAs https://app.dimensions.ai/details/publication/pub.1055956088
    249 rdf:type schema:CreativeWork
    250 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
    251 rdf:type schema:CreativeWork
    252 https://doi.org/10.1056/nejmra0708126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043717119
    253 rdf:type schema:CreativeWork
    254 https://doi.org/10.1093/neuonc/not151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003959313
    255 rdf:type schema:CreativeWork
    256 https://doi.org/10.1158/0008-5472.can-07-0127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010238020
    257 rdf:type schema:CreativeWork
    258 https://doi.org/10.1158/1078-0432.ccr-09-3106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014254065
    259 rdf:type schema:CreativeWork
    260 https://doi.org/10.1158/1535-7163.mct-10-0516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038106726
    261 rdf:type schema:CreativeWork
    262 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
    263 rdf:type schema:CreativeWork
    264 https://doi.org/10.1200/jco.1999.17.8.2572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549881
    265 rdf:type schema:CreativeWork
    266 https://doi.org/10.1200/jco.2005.04.8801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021574047
    267 rdf:type schema:CreativeWork
    268 https://doi.org/10.1200/jco.2008.16.3055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010751135
    269 rdf:type schema:CreativeWork
    270 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
    271 rdf:type schema:CreativeWork
    272 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
    273 rdf:type schema:CreativeWork
    274 https://doi.org/10.1200/jco.2010.28.15_suppl.8531 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083944555
    275 rdf:type schema:CreativeWork
    276 https://doi.org/10.1200/jco.2011.36.1311 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047945986
    277 rdf:type schema:CreativeWork
    278 https://doi.org/10.1200/jco.2011.39.3934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009031942
    279 rdf:type schema:CreativeWork
    280 https://doi.org/10.1200/jco.2012.41.9242 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042233716
    281 rdf:type schema:CreativeWork
    282 https://doi.org/10.1212/01.wnl.0000304121.57857.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064350042
    283 rdf:type schema:CreativeWork
    284 https://doi.org/10.1215/15228517-2006-025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064414261
    285 rdf:type schema:CreativeWork
    286 https://doi.org/10.1215/15228517-2007-062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046098276
    287 rdf:type schema:CreativeWork
    288 https://doi.org/10.1215/15228517-2009-006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011570339
    289 rdf:type schema:CreativeWork
    290 https://doi.org/10.1586/ern.11.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018407035
    291 rdf:type schema:CreativeWork
    292 https://doi.org/10.2217/cns.12.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037403239
    293 rdf:type schema:CreativeWork
    294 https://www.grid.ac/institutes/grid.16753.36 schema:alternateName Northwestern University
    295 schema:name Department of Neurology, Northwestern University, 710 N Lake Shore Drive, Abbott Hall, Room 1110, 60611, Chicago, IL, USA
    296 rdf:type schema:Organization
    297 https://www.grid.ac/institutes/grid.239578.2 schema:alternateName Cleveland Clinic
    298 schema:name Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, 9500 Euclid Avenue, Mailcode: NB40, 44195, Cleveland, OH, USA
    299 rdf:type schema:Organization
    300 https://www.grid.ac/institutes/grid.413480.a schema:alternateName Dartmouth–Hitchcock Medical Center
    301 schema:name Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, 03756, Lebanon, NH, USA
    302 rdf:type schema:Organization
    303 https://www.grid.ac/institutes/grid.414123.1 schema:alternateName Lucile Packard Children's Hospital
    304 schema:name Stanford University, 875 Blake Wilbur Dr Rm 2221, 943042205, Palo Alto, CA, USA
    305 rdf:type schema:Organization
    306 https://www.grid.ac/institutes/grid.429997.8 schema:alternateName Tufts University
    307 schema:name Tufts University, 750 Washington St, # 833, 02111, Boston, MA, USA
    308 rdf:type schema:Organization
    309 https://www.grid.ac/institutes/grid.50956.3f schema:alternateName Cedars-Sinai Medical Center
    310 schema:name Cedars Sinai Medical Center, 8631 W 3rd St, Ste 410-E, 90048, Los Angeles, CA, USA
    311 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...